CAMBRIDGE - Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, will host its third annual 'FutureCast: An R&D Portfolio Review' to showcase the Company's research and development strategy, and clinical progress in its depression, neurology, and neuropsychiatry franchise programs.

'Sage's expertise in brain circuitry, including our deep understanding of the GABAA and NMDA receptor pathways, has resulted in a rich portfolio that includes multiple opportunities to deliver life-changing brain health medicines, if we're successful,' said Barry Greene, Chief Executive Officer at Sage Therapeutics. 'Over the last decade, the devastating impact of brain health disorders and the absence of innovation have resulted in significant costs to individuals, families, and society. We believe our productive, proactive, predictive, and patient-focused approach to drug development may enable us to deliver innovative treatments that meet patient needs. We look forward to advancing this work in 2022.'

Clinical Program Updates

Sage is advancing a portfolio of novel and differentiated product candidates designed to improve brain health by targeting the GABA and NMDA receptor systems. Dysfunction in these systems is known to be at the core of numerous disorders.

About Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.

Contact:

Helen Rubenstein

Tel: 315-382-3919

Email: helen.rubenstein@sagerx.com

(C) 2021 Electronic News Publishing, source ENP Newswire